Taiyo Pharmaceutical Voluntarily Recalls 112.8 Million Injectables
This article was originally published in PharmAsia News
Executive Summary
Nagoya-based Taiyo Pharmaceutical announced a recall Jan. 13 in the Japanese market for pain reliever Nolport (extract of vaccinated rabbit skin) injections
|
Nagoya-based Taiyo Pharmaceutical announced a recall Jan. 13 in the Japanese market for pain reliever Nolport (extract of vaccinated rabbit skin) injections. The recall targets 11,283,050 injections manufactured from October 2008 to January 2011. The recall was initiated due to the product's active ingredient extraction process, which was different from what was specified by the manufacturing approval application. The company said the API manufacturing was contracted to a maker in China, and the maker had used the different process. The manufacturing discrepancy was discovered after Taiyo switched the maker and Japan's Pharmaceutical and Medical Device Agency conducted an audit. Taiyo said there are no adverse effect reports related to the recall. (Click here for more - Japanese language) "Taiyo Voluntarily Recalls 112.8 Million Pain Relief Injections" - CB News (1/14/2010) |